Drug trials in epilepsy: New drugs have been poorly assessed

British Medical Journal

Volumn 313, Issue 7066, 1996, Pages 1158-

  Mignot, Gilles ^a  

^a La Revue Prescrire   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; FELBAMATE; GABAPENTIN; LAMOTRIGINE; VIGABATRIN;

CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG EFFICACY; EDITORIAL; EPILEPSY; EYE TOXICITY; HUMAN; METHODOLOGY; NEUROTOXICITY; PRIORITY JOURNAL; SEIZURE; TREATMENT FAILURE;

ANTICONVULSANTS; DRUG EVALUATION; EPILEPSY; HUMANS;

EID: 33646836642     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Shorvon SD. Medical assessment and treatment of chronic epilepsy. BMJ 1991;302:363-6.
2. Vigabamn. Prescrire International 1992;l(l):3-4.
3. Vigabamn and childhood epilepsy. Prescrire International 1993;2(5):22-3.
4. Lamotrigine. Prescrire International (in press).
5. Marson AG, Kadir ZA, Chadwick DW. The new anriepileptic drugs: a systematic review of iheir efficacy amnd tolerability. BMJ 1996;313:1169-74.
6. Chadwick D. Measuring antiepileptic therapies: the patient vs the physician view point. Neurology I994;44 (supp! 8):S24-8.
7. Walker MC, Li LM, Sander JWAS. Long term use of the new anri-epilepric drugs, lamotrigine and \igabatrin in severe refractory epilepsy. R\fJ1996;313:l 184-5.